Power3 Launches First Proteomic Breast Cancer Diagnostic in the Middle East | GenomeWeb
Power3 Medical Products this week said it is launching its blood-based breast cancer test in the Middle East, making it the first proteomic test for the early screening and diagnosis of the disease.
The company, based in The Woodlands, Texas, has signed an agreement with Financial Advisory Houses’ Medical Equipment Suppliers division to market and distribute the test, called BC-SeraPro, in Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Saudi Arabia, Oman, Qatar, Syria, the United Arab Emirates, and Yemen.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.